Positioning Ganglioside D3 as an Immunotherapeutic Target in Lymphangioleiomyomatosis-Reference-Cited by-同舟云学术

Positioning Ganglioside D3 as an Immunotherapeutic Target in Lymphangioleiomyomatosis

Published:2013-07 Issue:1 Volume:183 Page:226-234
ISSN:0002-9440
Container-title:The American Journal of Pathology
language:en
Short-container-title:The American Journal of Pathology

Author:

Gilbert Emily R.,Eby Jonathan M.,Hammer Adam M.,Klarquist Jared,Christensen David G.,Barfuss Allison J.,Boissy Raymond E.,Picken Maria M.,Love Robert B.,Dilling Daniel F.,Le Poole I. Caroline

Publisher

Elsevier BV

Subject

Pathology and Forensic Medicine

Reference40 articles.

1. Survival and disease progression in UK patients with lymphangioleiomyomatosis;Johnson;Thorax,2004

2. Rare diseases. 1. Lymphangioleiomyomatosis: clinical features, management and basic mechanisms;Johnson;Thorax,1999

3. A current viewpoint of lymphangioleiomyomatosis supporting immunotherapeutic treatment options;Dilling;Am J Respir Cell Mol Biol,2012

4. The spectrum of mutations in TSC1 and TSC2 in women with tuberous sclerosis and lymphangiomyomatosis;Strizheva;Am J Respir Crit Care Med,2001

5. Lymphangioleiomyomatosis and tuberous sclerosis complex;Chorianopoulos;Lung,2008

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dysregulated lipid metabolism in lymphangioleiomyomatosis pathogenesis as a paradigm of chronic lung diseases;Frontiers in Medicine;2023-01-19

2. Benign tumors in TSC are amenable to treatment by GD3 CAR T cells in mice;JCI Insight;2021-11-22

3. Immunotherapy for Lymphangioleiomyomatosis and Tuberous Sclerosis;Chest;2019-12

4. Human pluripotent stem cell modeling of tuberous sclerosis complex reveals lineage-specific therapeutic vulnerabilities;2019-06-27

5. Immune Checkpoint Ligand PD-L1 Is Upregulated in Pulmonary Lymphangioleiomyomatosis;American Journal of Respiratory Cell and Molecular Biology;2018-12